Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Market Trajectory & Analytics

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market to Reach $5.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$5.7 Billion by 2027, growing at a CAGR of 9.7% over the period 2020-2027. Medication, one of the segments analyzed in the report, is projected to record 7.7% CAGR and reach US$3.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Other Treatments segment is readjusted to a revised 14.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $881.8 Million, While China is Forecast to Grow at 9.2% CAGR

The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market in the U.S. is estimated at US$881.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$994 Million by the year 2027 trailing a CAGR of 9.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.7% and 8.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Select Competitors (Total 40 Featured):

• Achillion Pharmaceuticals
• Akari Therapeutics
• Alexion Pharmaceuticals
• Amgen Inc.
• Apellis Pharmaceuticals
• F. Hoffmann-La Roche AG.
• GE Healthcare
• Johnson & Johnson
• Ra Pharmaceuticals
• Regeneron Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited (Shire Plc)
• Thermo Fisher Scientific Inc.